Literature DB >> 15817666

Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice.

C Cristina1, G Díaz-Torga, A Baldi, A Góngora, M Rubinstein, M J Low, D Becú-Villalobos.   

Abstract

Vascular endothelial growth factor (VEGF)-A is an important angiogenic cytokine in cancer and pathological angiogenesis and has been related to the antiangiogenic activity of dopamine in endothelial cells. We investigated VEGF expression, localization, and function in pituitary hyperplasia of dopamine D2 receptor (D2R)-knockout female mice. Pituitaries from knockout mice showed increased protein and mRNA VEGF-A expression when compared with wild-type mice. In wild-type mice, prolonged treatment with the D2R antagonist, haloperidol, enhanced pituitary VEGF expression and prolactin release, suggesting that dopamine inhibits pituitary VEGF expression. VEGF expression was also increased in pituitary cells from knockout mice, even though these cells proliferated less in vitro when compared with wild-type cells, as determined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium proliferation assay, proliferating cell nuclear antigen expression, and [(3)H]thymidine incorporation. In contrast to other animal models, estrogen did not increase pituitary VEGF protein and mRNA expression and lowered serum prolactin secretion in vivo and in vitro in both genotypes. VEGF (10 and 30 ng/ml) did not modify pituitary cell proliferation in either genotype and increased prolactin secretion in vitro in estrogen-pretreated cells of both genotypes. But conditioned media from D2R(-/-) cells enhanced human umbilical vein cell proliferation, and this effect could be partially inhibited by an anti-VEGF antiserum. Finally, using dual-labeling immunofluorescence and confocal laser microscopy, we found that in the hyperplastic pituitaries, VEGF-A was mostly present in follicle-stellate cells. In conclusion, pituitary VEGF expression is under dopaminergic control, and even though VEGF does not promote pituitary cellular proliferation in vitro, it may be critical for pituitary angiogenesis through paracrine actions in the D2R knockout female mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15817666     DOI: 10.1210/en.2004-1445

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  23 in total

1.  VEGF and CD31 association in pituitary adenomas.

Authors:  Carolina Cristina; María Inés Perez-Millan; Guillermina Luque; Raúl Ariel Dulce; Gustavo Sevlever; Silvia Inés Berner; Damasia Becu-Villalobos
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

2.  Subcellular localisation of VEGF in different pituitary cells. Changes of its expression in oestrogen induced prolactinomas.

Authors:  Jorge Humberto Mukdsi; Ana Lucía De Paul; Silvina Gutiérrez; Félix Daniel Roth; Agustín Aoki; Alicia Inés Torres
Journal:  J Mol Histol       Date:  2006-05-19       Impact factor: 2.611

3.  Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1).

Authors:  M Victoria Recouvreux; M Andrea Camilletti; Daniel B Rifkin; Damasia Becu-Villalobos; Graciela Díaz-Torga
Journal:  Endocrinology       Date:  2012-06-14       Impact factor: 4.736

Review 4.  The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.

Authors:  M Victoria Recouvreux; M Andrea Camilletti; Daniel B Rifkin; Graciela Díaz-Torga
Journal:  J Endocrinol       Date:  2015-12-23       Impact factor: 4.286

Review 5.  Gene therapy for pituitary tumors.

Authors:  Adriana Seilicovich; Daniel Pisera; Sandra A Sciascia; Marianela Candolfi; Mariana Puntel; Weidong Xiong; Gabriela Jaita; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

6.  Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers.

Authors:  María Susana Mallea-Gil; Carolina Cristina; María Inés Perez-Millan; Ana M Rodriguez Villafañe; Carolina Ballarino; Graciela Stalldecker; Damasia Becu-Villalobos
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

7.  Enhanced nestin expression and small blood vessels in human pituitary adenomas.

Authors:  María Inés Perez-Millan; Silvia Inés Berner; Guillermina María Luque; Cristian De Bonis; Gustavo Sevlever; Damasia Becu-Villalobos; Carolina Cristina
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

8.  The characteristic change in the distribution of S-100 immunoreactive folliculostellate cells in rat anterior pituitary upon long-term estrogen treatment is prevented by concomitant progesterone treatment.

Authors:  Andrea Heinzlmann; Katalin Köves
Journal:  Endocrine       Date:  2008-06       Impact factor: 3.633

Review 9.  Neuroendocrine Regulation of Metabolism.

Authors:  M P Cornejo; S T Hentges; M Maliqueo; H Coirini; D Becu-Villalobos; C F Elias
Journal:  J Neuroendocrinol       Date:  2016-07       Impact factor: 3.627

10.  Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.

Authors:  M Jian; Q Du; D Zhu; Z Mao; X Wang; Y Feng; Z Xiao; H Wang; Y Zhu
Journal:  J Endocrinol Invest       Date:  2018-10-28       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.